Particle.news
Download on the App Store
4 ARTICLES
·
1h ago

UK Opens Phase 2 Trial of mRNA EBV Vaccine for Newly Diagnosed MS Patients

Led by the University of Edinburgh with Moderna sponsorship, the study will enroll about 180 people to look for early signals of benefit.

image: ©monkeybusinessimages | iStock
Image
Image

Overview

  • The Horizon study is now recruiting in the UK, the first country outside the US to open sites, with up to 10 locations involved.
  • The trial tests whether suppressing Epstein–Barr virus can reduce new multiple sclerosis disease activity in recently diagnosed adults.
  • Participants must be aged 18 to 55 and have received an MS diagnosis within the past two years.
  • The investigational mRNA vaccine is designed to train the immune system to keep EBV suppressed and prevent viral reactivation.
  • The Phase 2 trial will run for roughly two and a half years and is presented by UK agencies as part of a broader strategic partnership with Moderna.